instruction:
Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
question:
"Although the story mentions the cost of immunosuppressant drugs, the story does not mention the cost of the new transplant technique. Given the preliminary nature of the findings, it is not yet possible to quantify the benefits of the new transplantation technique. The story does not mention any potential harms of the therapy. The story adequately describes the strength of the available evidence. The story describes thestudies as ""preliminary"" and brings attention tothe very small sample sizes. However, the story could have made less use of such terms as ""groundbreaking"" and ""breakthrough"" to describe the treatment in light of the preliminary nature of the findings. The story does not exaggerate the prevalence or seriousness of kidney disease. The story quotes multiple experts The story mentions immunosuppressants with traditional transplantation as the alternative to the new transplant technique. The story clearly states that the transplant technique is experimental and is only being performed in a handful of medical centers. The story clearly states that the treatment is a new approach. Because the story quotes multiple sources, the reader can assume that the story did not rely on a press release as the sole source of information."
answer:
Some transplant patients OK without years of drug treatment

question:
Luke Miels, who joined GSK in September 2017 after a contract dispute with his former employer AstraZeneca, said picking the most promising projects and developing them quickly now takes precedence over spreading the risk of failure. "In the past, 10 programs were chosen, a budget for eight was allocated. Usually what happened was that time was the trade off that was made," he said in an interview. "Now what we do is we pick five or six programs, and concentrate investment there." GSK, like rivals, was in the habit of testing new drugs first on patients who had run out of other treatment options. If successful, it would try patients at an earlier stage of their disease, replacing older, established treatments. In today's market, where rivals in the United States and China catch up fast if a new class of drug shows promise, GSK has to run costly drug tests on humans in several settings at the same time, even if it means dropping other drug candidates. "Rather than do things sequentially, you do them in parallel, or as close to parallel as possible," Miels said. GSK, which is battling to return to profit growth, has taken this approach for instance with an experimental drug that for now goes by the code name of GSK'916 against multiple myeloma, a common and incurable type of blood cancer. Likewise, GSK doubled down on its quest to bring a drug known as GSK'165 to market as a rheumatoid arthritis treatment, even after initial results in a mid-stage drug trial did not show a clear enough reading. "This drug has very interesting effects on pain. That could potentially reduce the use of opioids and pain meds," Miels said. More trials will be run to make the pain argument more clearly, he added. GSK expects a decline of 5%-9% in adjusted earnings per share this year, excluding exchange rate moves, as it suffers from generic competition to its inhalable lung drug Advair and pressure from rival Gilead in HIV treatments. Miels said a tougher stance on drug prices by U.S. lawmakers and medical insurers was one of the reasons for the need for speed in bringing drugs to market - to try to remain ahead of competitors for as long as possible. At the same time, rapid growth in the Chinese market was spurring a more sophisticated healthcare system there, with local biotech groups quick to catch up with Western pioneers in drug development, producing similar drugs for their home market.
answer:
GSK pharma head flags need for speed in high-pressure drug market.

question:
Ceyhan says he, like many others in Turkey, has been driven to brewing his own beer by the high price of commercially produced alcoholic drinks and the hefty taxes imposed by Turkey's ruling Islamist-rooted AK Party. "I might never have started this if beer wasn't so expensive," the 25-year old university student said. Under President Tayyip Erdogan, a pious Muslim known for his dislike of alcohol, taxes on booze have increased steadily and now account for two thirds of the cost of some alcoholic drinks. From early 2003, when Erdogan came to power, to October 2017, prices of raki - a traditional aniseed-flavored spirit - have jumped by 665 percent and beer prices by 580 percent, according to data from the Turkish Statistics Institute (TUIK). "What surprised me when I got into this was the cost. If I can make it this cheaply, it's strange that commercial beers are so expensive," said Ceyhan. He makes beer from an online kit, while others brew cider, lagers and wine. Some also dilute shop-bought ethanol to make their version of vodka or raki. While only a small portion of Turkey's 80 million people drink alcohol regularly, many of those who do are determined not to be denied their tipple by the rising prices - even though drinking home-brewed alcohol is not without its risks. Following the latest 10 percent increase in alcohol duty, which came into effect in December, the number of people producing their own drinks has grown, distributors say. "It's like a hidden reflex, a desire to be self-sufficient. We don't know what will be restricted or what they will allow tomorrow," said a 58-year old brewer, who asked to remain anonymous fearing a potential backlash. "It's as easy as making coffee, but it's ready in about a month," said the civil servant from Ankara, who makes wines and beers of different flavors, including raspberry and coffee. He said a bottle of his homemade beer costs around a quarter of the price in the shops. Erdogan's distaste for alcohol stands in contrast to modern Turkey's founding father, Mustafa Kemal Ataturk, who championed secularism and was often pictured with a glass of raki. The president has criticized alcohol consumption as morally harmful to society, insisting that Turkey's national beverage is not raki but the non-alcoholic yoghurt drink ayran. As of 2013, all advertisements, promotions and sponsorships of alcohol and tobacco products have been banned in Turkey. Such products are frequently blurred out in television shows. The surging taxes have reduced the volume of commercial alcoholic drinks sold in Turkey, with beer sales falling 10 percent between 2012 and 2016, and raki sales dropping by nearly a quarter, according to data from Turkey's tobacco and alcohol watchdog (TAPDK). Cagatay Mekiker, marketing director for Turkey's second- largest producer and distributor of alcoholic beverages, Antalya Alkollu Icecekler, said sales of ethanol had risen as part of a "rebellion" against the tax rises. He did not give a figure for the increased ethanol sales but Arda Gurdal, marketing director at drinks company AFS Icecekler said sales rose by up to 5 or 6 percent in the past year. Since the December hike, tax now constitutes nearly two-thirds of the 93 lira ($24) price of a standard 70 centiliter bottle of raki at the supermarket. One bottle costs more than 6 percent of the minimum monthly wage in Turkey. A bottle of Antalya Alkollu Icecekler's ethanol sells for half that price at one of Turkey's main supermarket chains, and can make up to 4 liters of drink, brewers say. Mekiker said the final product from some mixtures was not "real raki". Even advocates of the home-mixed drinks admit that diluting ethanol with water and aniseed flavoring is not the same as making an authentic drink - and admit there are dangers. In 2015, several people in Turkey died of alcohol poisoning, predominantly from bootleg alcohol used in the mixing of raki, while others went blind from improperly mixing alcohols, which can have a purity level of up to 95 percent. For some, though, the over-riding factor is cost. "Am I crazy? Why would I bother making drinks of poor quality at home instead of drinking the fine ones if it wasn't for prices?" said 23-year old Memet Yucekaya, who uses ethanol.
answer:
Steep alcohol taxes drive Turkey's drinkers to home-brew.